Nkarta, Inc. NKTX R2K
Healthcare · Biotechnology · United States
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
READ MORE ›$3.25
+86.78% 1Y
Market & Price
Market Cap
$232.52M
Current Price
$3.25
High / Low (52W)
$3.49 / $1.66
Beta
0.89
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$4.39
Price to Book
0.74
P/S
-
EV/EBITDA
-0.73
Dividend Yield
-
Profitability & Returns
ROCE
-31.94%
ROE
-30.07%
ROA
-17.10%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.37
EPS (TTM)
$-1.35
Balance Sheet & Liquidity
Debt/Equity
0.26
Quick Ratio
12.75
Current Ratio
12.96
Debt
$75.00M
Total Assets
$404.21M
Current Assets
$282.51M
Working Capital
$260.25M
Ownership
Promoter Holding
4.88%
Chg in Prom Hold
-
FII / Inst Holding
80.45%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$77.09M
Total Revenue (TTM)
-
EBITDA
$-106.03M
Free Cash Flow
$-57.38M
Operating Cash Flow
$-87.29M
Shares Outstanding
71.55M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
2.86%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NKTX Nkarta, Inc. R2K | 3.25 | - | $232.52M | - | -31.94% | -30.07% | - | 2.86% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.31K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.56M | 27.19M | 27.29M | 30.96M | 30.88M |
| Operating Income | - | -4.67M | -5.91M | -9.41M | -10.36M | -13.75M | -19.48M | -21.63M | -22.43M | -26.10M | -27.61M | -30.26M | -34.31M | -36.86M | -29.29M | -32.76M | -30.71M | -33.79M | -36.56M | -27.19M | -27.29M | -30.96M | -30.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.27M | -24.86M | -24.98M | -28.70M | -28.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -31.98M | -22.98M | -21.71M | -27.41M | -27.83M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.08M | -4.84M | -2.67M | -8.71M | -51.06M | -13.69M | -19.37M | -21.54M | -22.35M | -25.99M | -26.92M | -28.34M | -30.82M | -33.29M | -25.64M | -29.52M | -24.99M | -28.34M | -31.98M | -22.98M | -21.71M | -27.41M | -27.83M |
| Diluted EPS | - | - | - | - | - | - | - | -0.66 | -0.68 | -0.79 | -0.61 | -0.58 | -0.63 | -0.68 | -0.52 | -0.58 | -0.34 | -0.39 | -0.43 | -0.31 | -0.29 | -0.37 | -0.37 |
| R&D Expense | - | 3.62M | 4.62M | 7.26M | 7.86M | 9.83M | 13.54M | 15.96M | 16.62M | 19.57M | 21.05M | 23.43M | 26.14M | 25.12M | 22.19M | 25.24M | 23.13M | 25.25M | 24.17M | 20.78M | 20.20M | - | 24.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 115.00K | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 118.95M | 131.65M | 128.19M | 122.00M |
| Operating Income | -22.35M | -51.51M | -86.43M | -118.95M | -131.65M | -128.19M | -122.00M |
| EBITDA | - | - | - | -116.32M | -125.78M | -119.04M | -112.80M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -113.84M | -117.50M | -108.79M | -104.08M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -21.08M | -91.36M | -86.08M | -113.84M | -117.50M | -108.79M | -104.08M |
| Diluted EPS | - | - | -2.62 | -2.61 | -2.40 | -1.60 | -1.41 |
| R&D Expense | 17.22M | 36.22M | 63.41M | 90.90M | 96.77M | 96.74M | 90.43M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 2.86% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +86.78% |
| 6 Months: | +79.56% |
| 3 Months: | +20.37% |
| 1 Month: | +20.82% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 48.41M | 337.65M | - | 472.94M | 378.88M | 501.20M | 404.21M |
| Current Assets | - | - | - | - | 360.69M | 253.07M | 273.34M | 282.51M |
| Cash & Equivalents | - | 20.61M | 96.69M | - | 37.49M | 31.04M | 27.87M | 39.63M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 14.08M | 16.43M | - | 100.73M | 105.60M | 93.23M | 91.88M |
| Current Liabilities | - | 8.16M | 8.83M | - | 22.05M | 23.33M | 18.92M | 22.27M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 82.93M | 88.34M | 80.27M | 76.42M |
| Total Equity | -5.40M | -25.48M | 321.22M | - | 372.21M | 273.29M | 407.98M | 312.32M |
| Shares Outstanding | - | - | - | - | 48.88M | 49.18M | 70.65M | 71.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.37M | -43.51M | - | -57.00M | -86.16M | -99.70M | -88.70M |
| Investing Cash Flow | -18.30M | -210.08M | - | -184.69M | 79.02M | -129.56M | 100.32M |
| Financing Cash Flow | 49.58M | 329.82M | - | 219.01M | 691.00K | 226.08M | 141.00K |
| Capital Expenditure | -1.93M | -7.51M | - | -47.11M | -28.15M | -4.41M | -1.21M |
| Free Cash Flow | -20.30M | -51.02M | - | -104.11M | -114.31M | -104.11M | -89.91M |
| Net Change in Cash | - | - | - | -22.68M | -6.45M | -3.17M | 11.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -19,433.9% | - | - | - | - | - | - |
| Net Margin % | -18,327.0% | - | - | - | - | - | - |
| ROE % | 82.7% | -28.4% | - | -30.6% | -43.0% | -26.7% | -33.3% |
| ROCE % | -55.5% | -15.7% | - | -26.4% | -37.0% | -26.6% | -31.9% |
Shareholding Pattern
Insiders
4.88%
Institutions
80.45%
Public Float
84.58%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 15.10% | 10.81M | $35.12M |
| 2 | Blackrock Inc. | 6.30% | 4.51M | $14.65M |
| 3 | NEA Management Company, LLC | 4.99% | 3.57M | $11.60M |
| 4 | Samsara BioCapital, LLC | 4.90% | 3.51M | $11.40M |
| 5 | SR One Capital Management, LP | 4.66% | 3.33M | $10.83M |
| 6 | GSK plc | 4.40% | 3.15M | $10.24M |
| 7 | Monaco Asset Management SAM | 3.52% | 2.52M | $8.20M |
| 8 | Alyeska Investment Group, L.p. | 2.91% | 2.08M | $6.78M |
| 9 | Two Sigma Investments, LP | 2.86% | 2.05M | $6.65M |
| 10 | Vanguard Capital Management LLC | 2.81% | 2.01M | $6.54M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NKTX
No recent headlines available.